Konruns Pharma came on board as Nuance closed a round that will fund the clinical progress of its small molecule anti-tumour drug candidate.
China-based speciality drug developer Nuance Pharma received $181m in series D financing on Tuesday from investors including pharmaceutical company Konruns Pharma.
State-backed private equity GT Fund and biopharma-focused investment firm RTW Investments co-led the round, which was also backed by healthcare investment firm CBC Group, venture capital firm Matrix Partners China and investment firm HBM Healthcare Investments.
Founded in 2014, Nuance is working on therapeutics for respiratory diseases as well as disorders such as iron-deficiency anaemia and the management of…
